Directorate Change

ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces the resignation of Martin Lampshire as a Non-Executive Director of the Company, effective from 18 October 2024.

Martin has decided to step down from the Board of ValiRx to concentrate on his other commitments.

During Martin's four year tenure as a ValiRx Non-Executive Director, he has made significant contributions to the development of the strategy and helped the Company build relationships with various City stakeholders.

Martin Gouldstone, Chairman of ValiRx commented "I would very much like to extend my sincere appreciation to Martin for his contributions whilst serving as Non Executive Director for ValiRx. He has been a great support of the Company during the short time that both myself and Mark Eccleston have been in our respective roles and has helped with identifying further cost reductions that ValiRx can make in the short term to allow us to concentrate on the Company's longer term commercial and strategic objectives."

Mark Eccleston, CEO of ValiRx commented " I too would like to thank Martin for his contribution and guidance in my limited tenure to date. As ValiRx moves forward the board will evolve to bring more commercial and clinical development experience which, alongside cost savings in the range of £100, 000 we have identified, will focus the Company on building its therapeutic pipeline."

The Directors of the Company take responsibility for this announcement.